摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(3,4-Dihydro-2H-quinolin-1-yl)-2-{4-ethyl-5-[(4-fluoro-phenylamino)-methyl]-4H-[1,2,4]triazol-3-ylsulfanyl}-ethanone

中文名称
——
中文别名
——
英文名称
1-(3,4-Dihydro-2H-quinolin-1-yl)-2-{4-ethyl-5-[(4-fluoro-phenylamino)-methyl]-4H-[1,2,4]triazol-3-ylsulfanyl}-ethanone
英文别名
1-(3,4-dihydro-2H-quinolin-1-yl)-2-[[4-ethyl-5-[(4-fluoroanilino)methyl]-1,2,4-triazol-3-yl]sulfanyl]ethanone
1-(3,4-Dihydro-2H-quinolin-1-yl)-2-{4-ethyl-5-[(4-fluoro-phenylamino)-methyl]-4H-[1,2,4]triazol-3-ylsulfanyl}-ethanone化学式
CAS
——
化学式
C22H24FN5OS
mdl
——
分子量
425.5
InChiKey
OCPQRJZNIIWJJG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    30
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.32
  • 拓扑面积:
    88.4
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • [EN] PHARMACEUTICAL USE OF SUBSTITUTED 1,2,4-TRIAZOLES<br/>[FR] UTILISATION PHARMACEUTIQUE DE 1,2,4-TRIAZOLES SUBSTITUEES
    申请人:NOVO NORDISK AS
    公开号:WO2004089367A1
    公开(公告)日:2004-10-21
    The use of substituted 1,2,4-triazoles for modulating the activity of 11 β-hydroxysteroid dehydrogenase type 1 (11 βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of substituted 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11 βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    已描述了使用取代的1,2,4-三唑来调节11β-羟基甾醇脱氢酶1(11βHSD1)活性以及将这些化合物用作药物组合物的用途。还描述了一类新型的取代的1,2,4-三唑,它们在治疗中的用途,包含这些化合物的药物组合物,以及它们在制造药物中的用途。这些化合物是11βHSD1活性的调节剂,更具体地是抑制剂,并且可能在治疗、预防和/或预防一系列需要降低细胞内活性糖皮质激素浓度的医学疾病中有用。
  • Pharmaceutical use of substituted 1,2,4-triazoles
    申请人:Andersen Sune Henrik
    公开号:US20060100235A1
    公开(公告)日:2006-05-11
    The use of substituted 1,2,4-triazoles for modulating the activity of 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) and the use of these compounds as pharmaceutical compositions has been described. Also a novel class of substituted 1,2,4-triazoles, their use in therapy, pharmaceutical compositions comprising the compounds, as well as their use in the manufacture of medicaments has been described. The present compounds are modulators and more specifically inhibitors of the activity of 11βHSD1 and may be useful in the treatment, prevention and/or prophylaxis of a range of medical disorders where a decreased intracellular concentration of active glucocorticoid is desirable.
    使用替代1,2,4-三唑来调节11β-羟基类固醇脱氢酶1型(11βHSD1)的活性,并将这些化合物用作制药组合物已被描述。还描述了一种新的替代1,2,4-三唑类,它们在治疗中的用途,包含这些化合物的制药组合物,以及它们在制药中的用途。这些化合物是11βHSD1活性的调节剂,更具体地是抑制剂,可能在治疗、预防和/或预防一系列医学疾病中有用,其中降低细胞内活性糖皮质激素的浓度是可取的。
  • Combinations of an 11-beta-hydroxysteroid dehaydrogenase type 1 inhibitor and a glucocorticoid receptor agonist
    申请人:NOVO NORDISK A/S
    公开号:EP1854487A2
    公开(公告)日:2007-11-14
    Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and a glucocorticoid receptor agonist for treating some forms of cancer, diseases and disorders having inflammation as a component, and to minimize the side effects associated with glucorticoid receptor agonist therapy.
    由 11β- 羟类固醇脱氢酶 1 型抑制剂和糖皮质激素受体激动剂组成的联合疗法,用于治疗某些形式的癌症、以炎症为组成部分的疾病和失调,并最大限度地减少与糖皮质激素受体激动剂疗法相关的副作用。
  • Combination therapy using an 11B-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders
    申请人:NOVO NORDISK A/S
    公开号:EP1862181A2
    公开(公告)日:2007-12-05
    Combination therapy comprising the administration of an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent useful for treating, preventing and reducing the risk of developing insulin resistance, dyslipidemia, obesity, hypertension and other related diseases and disorders.
    由 11β- 羟类固醇脱氢酶 1 型抑制剂和降压药组成的联合疗法,可用于治疗、预防和降低胰岛素抵抗、血脂异常、肥胖、高血压及其他相关疾病和紊乱的发病风险。
  • Compositions for inhibition of insect sensing
    申请人:Vanderbilt University
    公开号:US10188105B2
    公开(公告)日:2019-01-29
    In one aspect, the invention relates to chemical modulators of insect olfactory receptors. In particular, compounds and compositions are provided that can inhibit sensory (e.g., host targeting) functions in airborne insects such as mosquitoes. Method of employing such agents, and articles incorporating the same, are also provided. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    一方面,本发明涉及昆虫嗅觉受体的化学调节剂。特别是,本发明提供了可抑制蚊子等空气传播昆虫的感官(如宿主靶向)功能的化合物和组合物。此外,还提供了使用此类制剂的方法以及含有此类制剂的物品。本摘要旨在作为一种扫描工具,用于特定技术领域的搜索,而非对本发明的限制。
查看更多